此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Curcumin-Piperine Supplementation in Fibromyalgia

2026年8月9日 更新者:Marina Khalil、Ain Shams University

Evaluation of the Effect of Curcumin and Piperine Supplementation on Clinical Outcome in Fibromyalgia Patients.

The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo.

Participants will:

Be randomly assigned to receive either curcumin and piperine supplements or a placebo.

Attend scheduled clinic visits for clinical assessments and blood sample collection.

Complete study questionnaires before and after treatment time frame.

The primary question the study aim to answer is:

Does Curcumin-piperine supplementation reduce pain intensity by Visual Analog Scale (VAS), compared with placebo?

The secondary questions this study aims to answer are:

Does supplementation improve fibromyalgia disease impact and quality of life? Does supplementation improve inflammatory biomarkers and oxidative stress? Does supplementation improve insulin resistance? Is curcumin and piperine supplementation safe and well tolerated?

研究概览

详细说明

Fibromyalgia (FM) is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive impairment, and mood disorders. Increasing evidence suggests that its pathogenesis is driven by a complex interaction of central sensitization, neuroinflammation, and oxidative stress. Elevated levels of pro-inflammatory cytokines and oxidative stress biomarkers have been linked to pain severity and disease progression. Although current pharmacological therapies can reduce symptoms, their effectiveness is often limited, and they do not adequately address the underlying biological mechanisms.

In addition to inflammation and oxidative stress, insulin resistance (IR) has recently emerged as a potential contributor to fibromyalgia. Several clinical studies have reported higher HOMA-IR values in patients with FM than in healthy individuals, with greater insulin resistance being associated with more severe pain and poorer clinical outcomes. This relationship may be explained by chronic low-grade inflammation, increased oxidative stress, impaired glucose metabolism, and altered central pain processing. These findings suggest that metabolic dysfunction may contribute to symptom persistence and represent an additional therapeutic target in FM.

Curcumin, a natural polyphenol extracted from "Curcuma longa", has attracted considerable interest because of its anti-inflammatory, antioxidant, neuroprotective, and analgesic properties. In addition to reducing inflammatory mediators, oxidative stress, and modulating pain pathways, curcumin has been shown to improve insulin sensitivity and glycemic control, suggesting that it may simultaneously target both the inflammatory and metabolic abnormalities associated with FM.

These findings support the hypothesis that curcumin may improve fibromyalgia by addressing inflammation, oxidative stress, pain sensitization, and metabolic dysfunction. However, current clinical evidence remains limited by small sample sizes and short intervention periods. Furthermore, curcumin's poor oral bioavailability can be markedly enhanced by co-administration with piperine, which increases its intestinal absorption. Therefore, a well-designed randomized controlled trial is needed to evaluate the efficacy and safety of curcumin-piperine supplementation as an adjunctive therapy for patients with fibromyalgia.

A total of 80 fibromyalgia patients will be enrolled in the study. Patients will be stratified according to insulin resistance status (insulin-resistant vs. non-insulin-resistant) followed by permuted block randomization to the study groups. All patients in both groups will receive standard treatment consisting of duloxetine and gabapentin, along with personalized guidance on an anti-inflammatory diet and exercise program.

Participants will be educated about the study and asked to sign a written informed consent before starting the study, assuring that they can withdraw at any time if they want.

The following data will be collected from patient records and by history taking from the patients upon enrollment:

A. Patient demographics including age, gender, weight, height, and body mass index (BMI).

B. Clinical variables including HbA1c, and HOMA-IR, complete blood picture, kidney function tests and liver function tests C. Comorbidities including but not limited to diabetes, hypertension, chronic kidney disease, cardiovascular disease, and immunosuppression.

D. Medical history including previous hospitalizations, surgeries, medication history, and known drug allergies.

E. Medication history including analgesic consumption (dose, frequency, and duration)

The patients will be followed up by weekly phone calls to encourage adherence and to evaluate the incidence and severity of the adverse effects including GIT disturbances or any other undesirable side effects reported by the patients throughout the trial. In addition, complete blood picture, kidney function tests, and liver function tests will be assessed at baseline, after 1 month and by the end of the study (after 3 months).

研究类型

介入性

注册 (估计的)

80

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Ismailia、埃及、41511
        • Suez Canal University hospitals
        • 接触:
          • Rheumatology and Rehabilitation Outpatient Clinic
          • 电话号码:+201277884948
        • 首席研究员:
          • marina w khalil, M.Sc candidate
        • 副研究员:
          • Maha Abd El-Fattah, Associate Professor of Rheumat

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Adult women aged ≥18 years.
  • Patients with confirmed diagnosis of fibromyalgia, according to 2022 ACR Fibromyalgia criteria.

Exclusion Criteria:

  • Diabetic patients (HbA1c ≥ 6.5).
  • Patients with chronic inflammatory or autoimmune diseases other than FM.
  • Patients allergic to curcumin or piperine.
  • Patients receiving other anti-inflammatory medications.
  • Severe hepatic or renal impairment.
  • Patients receiving anticoagulant medications (e.g., clopidogrel).
  • Pregnancy or lactation.
  • Participation in another clinical trial

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Group A (Curcumin Group)
The experimental group will receive Organic Nation Curcumin® oral coated tablets, administered once daily for 3 months, containing 1,200 mg of standardized curcumin (95% turmeric extract) combined with 10 mg of piperine (95% black pepper extract), in addition to the standard treatment.
The experimental group will receive Organic Nation Curcumin® oral coated tablets, administered once daily for 3 months, containing 1,200 mg of standardized curcumin (95% turmeric extract) combined with 10 mg of piperine (95% black pepper extract).
安慰剂比较:Group B (Placebo Group)
Participants will receive identical-appearing tablets containing inert excipients once daily for 3 months, in addition to the standard treatment.
the placebo group will receive matching oral placebo tablet containing inert excipients for the same duration. The placebo tablets will be identical in appearance, size, color, and packaging to the active supplement to maintain blinding.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Assessment of pain severity measured by the Visual Analog Scale (VAS)
大体时间:3 months
VAS is a self-administered instrument widely used in fibromyalgia research and clinical practice to assess pain intensity and monitor treatment response. The VAS uses a 10-cm horizontal line anchored by 0 (no pain) and 10 (worst imaginable pain). It will be measured at baseline, after 1 month, and after 3 months.
3 months

次要结果测量

结果测量
措施说明
大体时间
The Revised Fibromyalgia Impact Questionnaire (FIQR)
大体时间:3 months
is a disease-specific, patient-reported outcome measure designed to assess disease severity and the overall impact of fibromyalgia. It comprises 21 items grouped into three domains: function (9 items assessing physical activities), overall impact (2 items evaluating the extent to which fibromyalgia interferes with goal achievement and causes a feeling of being overwhelmed), and symptoms (10 items assessing pain, fatigue, sleep quality, stiffness, depression, anxiety, memory, balance, tenderness, and environmental sensitivity). All items are rated on a 0-10 numeric scale. The total FIQR score ranges from 0 to 100, with higher scores indicating greater disease impact and symptom severity. It will be measured at baseline, after 1 month, and after 3 months
3 months
The 36-Item Short Form Health Survey (SF-36)
大体时间:3 months
SF-36 is a validated, self-administered, generic instrument used to assess health-related quality of life in fibromyalgia research by evaluating both physical and mental health status. It consists of 36 items covering eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Domain scores are transformed to a scale ranging from 0 to 100, where 0 represents the worst and 100 the best perceived health status, and are aggregated into two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). It will be measured at baseline, after 1 month, and after 3 months
3 months
Serum inflammatory biomarkers: IL-6
大体时间:3 months
Collected serum samples will be stored at -80 C until analysis. Serum IL-6 will be assessed using enzyme-linked immunosorbent assay (ELISA) kits. It will be measured at the start and end of the study (after 3 months).
3 months
Serum oxidative biomarker: MDA
大体时间:3 months
Collected serum samples will be stored at -80oC until analysis. Serum MDA will be assessed for each patient using spectrophotometric assay kits. It will be measured at the start and end of the study (after 3 months).
3 months
Glycemic markers: HOMA-IR
大体时间:3 months
Insulin resistance will be assessed using the HOMA-IR ( fasting insulin × fasting glucose / 405), which is calculated from fasting glucose and fasting insulin levels. Fasting blood glucose will be measured using an enzymatic colorimetric method, and fasting serum insulin will be determined using ELISA kits.It will be measured at the start and end of the study (after 3 months).
3 months
The Hospital Anxiety and Depression Scale (HADS)
大体时间:3 months
The scale consists of 14 self-reported items, divided equally into two domains: anxiety (HADS-A) and depression (HADS-D). Each item is rated on a 4-point Likert scale (0-3), yielding subscale scores ranging from 0 to 21, where higher scores indicate greater symptom severity. A cut-off score of ≥8 on either subscale is considered indicative of clinically relevant anxiety or depression. Elevated HADS scores in this population have been consistently associated with higher symptom severity, increased pain intensity, poorer sleep quality, reduced quality of life, and functional impairment. It will be measured at baseline, after 1 month, and after 3 months.
3 months
Incidence and severity of treatment-emergent adverse events
大体时间:3 months
The patients will be followed up by weekly phone calls to evaluate the incidence and severity of the adverse effects including GIT disturbances or any other undesirable side effects.
3 months
Change in alanine aminotransferase (ALT) level
大体时间:3 months
Serum alanine aminotransferase (ALT) level will be assessed at baseline and after 3 months. ALT will be reported in unit per liter (U/L)
3 months
Change in aspartate aminotransferase (AST) level
大体时间:3 months
Serum aspartate aminotransferase (AST) level will be assessed at baseline and after 3 months. AST will be reported in unit per liter (U/L)
3 months
Change in serum creatinine level
大体时间:3 months
Change in serum creatinine level will be assessed at baseline and after 3 months. Serum creatinine level will be reported in (mg/dL).
3 months
Change in hemoglobin level
大体时间:3 months
Hemoglobin level will be assessed at baseline and after 3 months. Hemoglobin will be reported in (g\dL).
3 months
Change in white blood cell count
大体时间:3 Months
white blood cell count will be assessed at baseline and after 3 months. white blood cell count will be reported as thousand cells per microliter
3 Months
Change in platelet count
大体时间:3 months
Platelet count will be assessed at baseline and after 3 months. Platelet count will be reported as thousand cells per microliter.
3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月1日

初级完成 (估计的)

2027年6月20日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2026年8月4日

首先提交符合 QC 标准的

2026年8月4日

首次发布 (实际的)

2026年8月7日

研究记录更新

最后更新发布 (实际的)

2026年8月11日

上次提交的符合 QC 标准的更新

2026年8月9日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅